<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0484-7903</journal-id>
<journal-title><![CDATA[Revista mexicana de anestesiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. anestesiol.]]></abbrev-journal-title>
<issn>0484-7903</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Anestesiología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0484-79032024000200091</article-id>
<article-id pub-id-type="doi">10.35366/115315</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[El postacondicionamiento del miocardio con remifentanil en el corazón aislado y perfundido de rata]]></article-title>
<article-title xml:lang="en"><![CDATA[Myocardial postconditioning with remifentanyl in the isolated perfused rat heart]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Luna-Ortiz]]></surname>
<given-names><![CDATA[Pastor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pilar-Báez]]></surname>
<given-names><![CDATA[Santiago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pastelín-Hernández]]></surname>
<given-names><![CDATA[Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Rosas]]></surname>
<given-names><![CDATA[Martín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Cardiología Ignacio Chávez Departamento de Farmacología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Cardiología Ignacio Chávez Departamento de Fisiología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Nacional de Cardiología Ignacio Chávez Departamento de Farmacología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Instituto Nacional de Cardiología Ignacio Chávez Departamento de Farmacología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Instituto Nacional de Cardiología Ignacio Chávez Departamento de Farmacología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Instituto Nacional de Cardiología Ignacio Chávez Departamento de Fisiología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>47</volume>
<numero>2</numero>
<fpage>91</fpage>
<lpage>95</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0484-79032024000200091&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0484-79032024000200091&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0484-79032024000200091&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: La isquemia miocárdica perioperatoria es un evento observado durante la cirugía en pacientes de alto riesgo y aumenta significativamente la morbimortalidad postoperatoria. El corazón puede tolerar los efectos de la lesión aguda por la isquemia-reperfusión (I/R) si se aplican varios ciclos cortos de I/R previos a la isquemia miocárdica sostenida. Esta estrategia cardioprotectora puede ser usada previamente (preacondicionamiento isquémico) o posteriormente (postacondicionamiento isquémico) al período de isquemia sostenida letal. El condicionamiento farmacológico consiste en el uso de fármacos para obtener efectos cardioprotectores similares al condicionamiento isquémico. Los opioides se han utilizado en el condicionamiento farmacológico, en particular el remifentanil es el más extensamente estudiado en la cardioprotección. Estudios previos demuestran que protege contra el daño por la I/R aplicándolo pre, trans y postreperfusión tanto en estudios experimentales como en la práctica clínica. En este trabajo se estudia el postacondicionamiento inducido con remifentanil en el modelo de Langendorff de corazón aislado y perfundido de rata. Este modelo permite reproducir la isquemia miocárdica en el corazón aislado de un animal anestesiado. Las variables registradas fueron: presión intraventricular izquierda (PVI), frecuencia cardíaca (FC) y actividad contráctil del corazón expresada como el trabajo cardíaco (TC = PVI × FC). La isquemia se produjo al suspender la perfusión de la solución Krebs-Henseleit durante 30 minutos, posteriormente se estableció la reperfusión durante dos horas, observándose la respuesta del corazón aislado en las diferentes condiciones. En los corazones control con I/R, el TC disminuyó un 40%. Por otro lado, el remifentanil recuperó los niveles basales de TC del control sin I/R, demostrando su efecto cardioprotector.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Perioperative myocardial ischemia can occur during surgery in high-risk patients, which could increase postoperative morbidity and mortality. The heart can tolerate the effects of acute ischemia-reperfusion (I/R) injury if several short cycles of I/R are applied prior to sustained myocardial ischemia. This strategy is used before (ischemic preconditioning) or after (ischemic postconditioning) sustained lethal ischemia. In pharmacological conditioning, drugs are used to obtain cardioprotective effects like ischemic preconditioning. Opioids have been used in pharmacological conditioning. Remifentanyl is the most extensively studied opioid in cardioprotection. Previous studies show that remifentanyl protects against I/R damage by applying it pre, trans and post-reperfusion in experimental studies and in clinical practice. In this work we studied the postconditioning induced with remifentanyl in the Langendorff model of isolated and perfused rat heart. This model reproduces myocardial ischemia in the heart isolated from an anesthetized animal. The variables recorded were left intraventricular pressure (LVP), heart rate (HR), and heart contractile activity expressed as cardiac work (TC = LVP × HR). Ischemia occurred when the perfusion was stopped for 30 minutes. Later, reperfusion was restored for two hours, observing the response of the isolated heart under the different conditions. In control hearts with I/R, the TC decreased by 40%. On the other hand, remifentanyl recovered the basal levels of TC control without I/R. Further studies are needed to evaluate the effectiveness of remifentanyl postconditioning in daily clinical practice.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[isquemia]]></kwd>
<kwd lng="es"><![CDATA[reperfusión]]></kwd>
<kwd lng="es"><![CDATA[postacondicionamiento]]></kwd>
<kwd lng="es"><![CDATA[remifentanil]]></kwd>
<kwd lng="es"><![CDATA[receptores opioides]]></kwd>
<kwd lng="en"><![CDATA[ischemia]]></kwd>
<kwd lng="en"><![CDATA[reperfusion]]></kwd>
<kwd lng="en"><![CDATA[post-conditioning]]></kwd>
<kwd lng="en"><![CDATA[remifentanyl]]></kwd>
<kwd lng="en"><![CDATA[opioid receptors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Biccard]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Detection and management of perioperative myocardial ischemia]]></article-title>
<source><![CDATA[Curr Opin Anaesthesiol]]></source>
<year>2014</year>
<volume>27</volume>
<page-range>336-43</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murry]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Jennings]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Reimer]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1986</year>
<volume>74</volume>
<page-range>1124-36</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Irwin]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil and opioid-induced cardioprotection]]></article-title>
<source><![CDATA[J Cardiothorac Vasc Anesth]]></source>
<year>2015</year>
<volume>29</volume>
<page-range>S23-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schultz]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Rose]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts]]></article-title>
<source><![CDATA[Am J Physiol]]></source>
<year>1995</year>
<volume>268</volume>
<page-range>H2157-61</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schultz]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart]]></article-title>
<source><![CDATA[J Mol Cell Cardiol]]></source>
<year>1997</year>
<volume>29</volume>
<page-range>2187-95</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schultz]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart]]></article-title>
<source><![CDATA[J Mol Cell Cardiol]]></source>
<year>1997</year>
<volume>29</volume>
<page-range>1355-62</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[WQ]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiplicity of kappa opioid receptor binding in the rat cardiac sarcolemma]]></article-title>
<source><![CDATA[J Mol Cell Cardiol]]></source>
<year>1996</year>
<volume>28</volume>
<page-range>1547-54</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zimlichman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gefel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Eliahou]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of opioid receptors during heart ontogeny in normotensive and hypertensive rats]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1996</year>
<volume>93</volume>
<page-range>1020-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benedict]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Benedict]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Bolling]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Opiate drugs and delta receptor-mediated myocardial protection]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1999</year>
<volume>100</volume>
<page-range>II357-60</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Headrick]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[See Hoe]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Du Toit]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
<name>
<surname><![CDATA[Peart]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Opioid receptors and cardioprotection - &#8216;opioidergic conditioning&#8217; of the heart]]></article-title>
<source><![CDATA[Br J Pharmacol]]></source>
<year>2015</year>
<volume>172</volume>
<page-range>2026-50</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roth]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Torregroza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Feige]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacological conditioning of the heart: an update on experimental developments and clinical implications]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2021</year>
<volume>22</volume>
<page-range>2519</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Spencer]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>1996</year>
<volume>52</volume>
<page-range>417-27</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Egan]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[Minto]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Hermann]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Barr]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Muir]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Shafer]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology. 1996;84:821-833]]></article-title>
<source><![CDATA[Erratum in: Anesthesiology]]></source>
<year>1996</year>
<volume>85</volume>
<page-range>695</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michelsen]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Salmenpera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hug]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Szlam]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[VanderMeer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anesthetic potency of remifentanil in dogs]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>1996</year>
<volume>84</volume>
<page-range>865-72</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beers]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Camporesi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil update: clinical science and utility]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2004</year>
<volume>18</volume>
<page-range>1085-104</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fletcher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Opioid-induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis]]></article-title>
<source><![CDATA[Br J Anaesth]]></source>
<year>2014</year>
<volume>112</volume>
<page-range>991-1004</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Irwin]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil preconditioning protects against ischemic injury in the intact rat heart]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>2004</year>
<volume>101</volume>
<page-range>918-23</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[ZD]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[WX]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil preconditioning lowers cardiac troponin I levels in patients undergoing off-pump coronary artery bypass graft surgery]]></article-title>
<source><![CDATA[Nan Fang Yi Ke Da Xue Xue Bao]]></source>
<year>2009</year>
<volume>29</volume>
<page-range>1554-6</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Ji]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Irwin]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: a randomized trial]]></article-title>
<source><![CDATA[J Cardiothorac Vasc Anesth]]></source>
<year>2010</year>
<volume>24</volume>
<page-range>790-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Landoni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Biondi-Zoccai]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil in cardiac surgery: a meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[J CardiothoracVascAnesth]]></source>
<year>2012</year>
<volume>26</volume>
<page-range>110-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanouz]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Yvon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guesne]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The in vitro effects of remifentanil, sufentanil, fentanyl, and alfentanil on isolated human right atria]]></article-title>
<source><![CDATA[AnesthAnalg]]></source>
<year>2001</year>
<volume>93</volume>
<page-range>543-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Saide Sahin A. Esra Atalik K et al. The in vitro effects of remifentanil and fentanyl on isolated human right atria and saphenous veins]]></article-title>
<source><![CDATA[J Cardiothorac Vasc Anesth]]></source>
<year>2003</year>
<volume>17</volume>
<page-range>465-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogletree]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Sprung]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moravec]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of remifentanil on the contractility of failing human heart muscle]]></article-title>
<source><![CDATA[J Cardiothoracic Vasc Anesth]]></source>
<year>2005</year>
<volume>19</volume>
<page-range>763-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Irwin]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation]]></article-title>
<source><![CDATA[Acta Anaesthesiol Scand]]></source>
<year>2010</year>
<volume>54</volume>
<page-range>510-8</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheng]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil induces cardio protection against ischemia/reperfusion injury by inhibiting endoplasmic reticulum stress through the maintenance of zinc homeostasis]]></article-title>
<source><![CDATA[Anesth Analg]]></source>
<year>2018</year>
<volume>127</volume>
<page-range>267-76</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Irwin]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil preconditioning confers delayed cardioprotection in the rat]]></article-title>
<source><![CDATA[Br J Anaesth]]></source>
<year>2007</year>
<volume>99</volume>
<page-range>632-8</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Irwin]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil preconditioning confers cardioprotection via cardiac kappa- and delta-opioid receptors]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>2005</year>
<volume>102</volume>
<page-range>371-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mukhomedzyanov]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Popov]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Maslov]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#948;2-Opioid receptors as a target in designing new cardioprotective drugs: the role of protein kinase C, AMPK, and sarcolemmal KATP channels]]></article-title>
<source><![CDATA[Bull Exp Biol Med]]></source>
<year>2022</year>
<volume>173</volume>
<page-range>33-6</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Roles of kappa opioid receptors in cardioprotection against ischemia: the signaling mechanisms]]></article-title>
<source><![CDATA[Sheng Li Xue Bao]]></source>
<year>2003</year>
<volume>55</volume>
<page-range>115-20</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Popov]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Mukhomedzyanov]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Maslov]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Infarct-reducing effect of the &#948;2 opioid receptor agonist deltorphin II: the molecular mechanism]]></article-title>
<source><![CDATA[Membranes (Basel)]]></source>
<year>2023</year>
<volume>13</volume>
<page-range>63</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mukhomedzyanov]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Tsibulnikov]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Krylatov]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Maslov]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative analysis of infarct size limiting activity of &#948;-opioid receptor agonists in reperfused heart in vivo]]></article-title>
<source><![CDATA[Bull Exp Biol Med]]></source>
<year>2021</year>
<volume>170</volume>
<page-range>604-7</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mukhomedzyanov]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Tsibulnikov]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Maslov]]></surname>
<given-names><![CDATA[LN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative analysis of infarct size limiting activity of &#954;-opioid receptor agonists in in vivo reperfused heart]]></article-title>
<source><![CDATA[Bull Exp Biol Med]]></source>
<year>2021</year>
<volume>170</volume>
<page-range>594-7</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lecour]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple protective pathways against reperfusion injury: a SAFE path without aktion?]]></article-title>
<source><![CDATA[J Mol Cell Cardiol]]></source>
<year>2009</year>
<volume>46</volume>
<page-range>607-9</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#954;-opioid receptor activation promotes mitochondrial fusion and enhances myocardial resistance to ischemia and reperfusion injury via STAT3-OPA1 pathway]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>2020</year>
<volume>874</volume>
<page-range>172987</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#954;-opioid receptor activation protects against myocardial ischemia-reperfusion injury via AMPK/Akt/eNOS signaling activation]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>2018</year>
<volume>833</volume>
<page-range>100-8</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[ZW]]></given-names>
</name>
<name>
<surname><![CDATA[Girwin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil mimics cardioprotective effect of ischemic preconditioning via protein kinase C activation in open chest of rats]]></article-title>
<source><![CDATA[Acta Pharmacol Sin]]></source>
<year>2005</year>
<volume>26</volume>
<page-range>546-50</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suleiman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Halestrap]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Griffiths]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitochondria: a target for myocardial protection]]></article-title>
<source><![CDATA[Pharmacol Ther]]></source>
<year>2001</year>
<volume>89</volume>
<page-range>29-46</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffiths]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Halestrap]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion]]></article-title>
<source><![CDATA[Biochem J]]></source>
<year>1995</year>
<volume>307</volume>
<page-range>93-8</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halestrap]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Javadov]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection]]></article-title>
<source><![CDATA[Cardiovasc Res]]></source>
<year>2004</year>
<volume>61</volume>
<page-range>372-85</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hausenloy]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Duchen]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Yellon]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury]]></article-title>
<source><![CDATA[Cardiovasc Res]]></source>
<year>2003</year>
<volume>60</volume>
<page-range>617-25</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Xi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Norfleet]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postconditioning prevents reperfusion injury by activating delta-opioid receptors]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>2008</year>
<volume>108</volume>
<page-range>243-50</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheng]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil induces cardio protection against ischemia/reperfusion injury by inhibiting endoplasmic reticulum stress through the maintenance of zinc homeostasis]]></article-title>
<source><![CDATA[AnesthAnalg]]></source>
<year>2018</year>
<volume>127</volume>
<page-range>267-76</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
<name>
<surname><![CDATA[Shim]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Kwak]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil protects myocardium through activation of anti-apoptotic pathways of survival in ischemia-reperfused rat heart]]></article-title>
<source><![CDATA[Physiol Res]]></source>
<year>2010</year>
<volume>59</volume>
<page-range>347-56</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Shao]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[JZ]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influences of remifentanil on myocardial ischemia-reperfusion injury and the expressions of Bax and Bcl-2 in rats]]></article-title>
<source><![CDATA[Eur Rev Med Pharmacol Sci]]></source>
<year>2018</year>
<volume>22</volume>
<page-range>8951-60</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewinska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Adamczyk-Grochala]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bloniarz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Remifentanil preconditioning protects against hypoxia-induced senescence and necroptosis in human cardiac myocytes in vitro]]></article-title>
<source><![CDATA[Aging]]></source>
<year>2020</year>
<volume>12</volume>
<page-range>13924-38</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
